All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2020-06-14T13:51:58.000Z

FDA accepts Biologics License Application of ropeginterferon alfa-2b for polycythemia vera

Jun 14, 2020
Share:

Bookmark this article

On June 4, 2020, the U.S. Food and Drug Administration (FDA) accepted a Biologics License Application (BLA) for ropeginterferon alfa-2b (P1101) for the treatment of polycythemia vera in the absence of symptomatic splenomegaly.1 The administration’s decision is expected at the beginning of next year.

Ropeginterferon alfa-2b is an investigational treatment comprising of structurally novel mono-pegylated proline interferon, designed for administration once every two weeks. The application was supported by the positive results of the phase III PROUD/CONTI-PV study, which compared the efficacy and safety of ropeginterferon alfa-2b (n = 95) with hydroxyurea/best available therapy (HU/BAT; n = 74) in patients with polycythemia vera.2 The novel agent induced higher response rates compared with HU/BAT, with rates increasing throughout 24 months of treatment. At 36 months, 66% vs 27% of patients reached a molecular response, and those responses were closely related to complete hematological response. In addition, responses were more durable with ropeginterferon alfa-2b than the comparator therapy (70.5% vs 51.4% of patients maintained a complete hematological response after 36 months). The safety profile of the investigational treatment was manageable, and similar rates of adverse events (mostly anemia, thrombocytopenia, and leukopenia) were reported in both treatment groups.

Ropeginterferon alfa-2b has previously been granted FDA’s orphan drug designation for the treatment of polycythemia vera and was approved for use in Europe in 2019.3

  1. U.S. FDA accepts PharmaEssentia’s application for ropeginterferon alfa-2b to treat polythycemia vera. http://www.pharmaessentia.com/en/news_latest. Published June 4, 2020. Accessed June 8, 2020.
  2. Gisslinger H, et al. Evidence for superior efficacy and disease modification after three years of prospective randomized controlled treatment of polycythemia vera patients with ropeginterferon alfa-2b vs. HU/BAT. Blood. 2018;132(Supplement 1):579. DOI: 1182/blood-2018-99-118715
  3. Besremi. https://www.ema.europa.eu/en/medicines/human/EPAR/besremi. Accessed June 8, 2020.

Your opinion matters

What do you consider to be the highest unmet need for patients with myelofibrosis?​
2 votes - 22 days left ...

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox